Zhejiang East Asia Pharmaceutical Co., Ltd. (SHA:605177)
China · Delayed Price · Currency is CNY 20.68
+0.24 (1.17%)
Apr 22, 2026, 11:28 AM CST
SHA:605177 Revenue
Zhejiang East Asia Pharmaceutical had revenue of 180.48M CNY in the quarter ending September 30, 2025, a decrease of -42.67%. This brings the company's revenue in the last twelve months to 831.56M, down -36.76% year-over-year. In the year 2024, Zhejiang East Asia Pharmaceutical had annual revenue of 1.20B, down -11.66%.
Revenue (ttm)
831.56M
Revenue Growth
-36.76%
P/S Ratio
2.77
Revenue / Employee
475.45K
Employees
1,749
Market Cap
2.30B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.20B | -158.21M | -11.66% |
| Dec 31, 2023 | 1.36B | 176.89M | 15.00% |
| Dec 31, 2022 | 1.18B | 467.34M | 65.62% |
| Dec 31, 2021 | 712.22M | -169.45M | -19.22% |
| Dec 31, 2020 | 881.67M | -106.42M | -10.77% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Shanghai Universal Biotech | 1.07B |
| Shandong Sito Bio-technology | 954.76M |
| Guangdong VTR Bio-Tech | 830.87M |
| Guiyang Xintian Pharmaceutical | 749.72M |
| Jilin Jian Yisheng Pharmaceutical | 640.17M |
| Hubei Goto Biopharm | 626.28M |
| Suzhou Fushilai Pharmaceutical | 439.57M |
| Shanghai Hile Bio-Technology | 246.35M |